Monthly Pubmed Review

Monthly Pubmed Review of the Most Relevant Research on Lung Cancer

Click here to sign up to receive our monthly PubMed review in your inbox! 

Literature Review, October 2018

BASIC AND APPLIED SCIENCE, PRE-CLINICAL STUDIES

Phosphorylation of nucleolin is indispensable to its involvement in the proliferation and migration of non-small cell lung cancer cells. Huang F1, Wu Y2, Tan H1, Guo T1, Zhang K1, Li D1, Tong Z1. Oncol Rep. 2018 Oct 12. doi: 10.3892/or.2018.6787. [Epub ahead of print]

A Transcriptomic Analysis of the Development of Skeletal Muscle Atrophy in Cancer-Cachexia in Tumor-Bearing Mice. Blackwell TA1, Cervenka I2, Khatri B3, et al. Physiol Genomics. 2018 Oct 5. doi: 10.1152/physiolgenomics.00061.2018. [Epub ahead of print]

Overexpressed C14orf166 associates with disease progression and poor prognosis in non-small-cell lung cancer. Zhou YW1, Li R2, Duan CJ3, Gao Y1, Cheng YD1, Zhang CF4. Biosci Rep. 2018 Sep 13;38(5). pii: BSR20180479. doi: 10.1042/BSR20180479. Print 2018 Oct 31.

Nanoscale Extracellular Vesicle-Derived DNA is Superior to Circulating Cell Free DNA for Mutation Detection in Early-Stage Non-Small Cell Lung Cancer. Wan Y1,2, Liu B3, Lei H4,5, et al. Ann Oncol. 2018 Oct 18. doi: 10.1093/annonc/mdy458. [Epub ahead of print]

Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy. Fumet JD1,2,3,4, Richard C2,3,4, Ledys F2,3,4, et al. Br J Cancer. 2018 Oct 15. doi: 10.1038/s41416-018-0220-9. [Epub ahead of print]

Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma. Yang Y1, Wang M1, Liu B1. J Cell Physiol. 2018 Oct 14. doi: 10.1002/jcp.27240. [Epub ahead of print]

PorphyrinHDL: A Novel Photosensitizing Nanoparticle for Lung Cancer Therapy. Ujiie H1, Ding L2, Fan R2, Kato T1, et al. Ann Thorac Surg. 2018 Oct 11. pii: S0003-4975(18)31462-0. doi: 10.1016/j.athoracsur.2018.08.053. [Epub ahead of print]

Metabolism of 4-methylimidazole in fischer 344 rats and B6C3F1 mice. Fennell TR1, Watson SL2, Dhungana S2, Snyder RW2. Food Chem Toxicol. 2018 Oct 11. pii: S0278-6915(18)30761-0. doi: 10.1016/j.fct.2018.10.032. [Epub ahead of print]

SCREENING, DIAGNOISIS AND STAGING

Reducing DNA damage by formaldehyde in liquid-based cytology preservation solutions to enable the molecular testing of lung cancer specimens. Matsuo Y1, Yoshida T2,3, Yamashita K3, Satoh Y1. Cancer Cytopathol. 2018 Oct 21. doi: 10.1002/cncy.22069. [Epub ahead of print]

Evaluating Shared Decision Making for Lung Cancer Screening. Brenner AT1,2, Malo TL2, Margolis M3, Elston Lafata J2,4, James S3, Vu MB3,5, Reuland DS1,2. JAMA Intern Med. 2018 Oct 1;178(10):1311-1316. doi: 10.1001/jamainternmed.2018.3054. 

Adequacy of Samples Obtained by Endobronchial Ultrasound with Transbronchial Needle Aspiration for Molecular Analysis in Patients with Non-Small Cell Lung Cancer. Systematic Review and Meta-Analysis. Labarca G1,2,3, Folch E3,4, Jantz M3,5, Mehta HJ3,5, Majid A3,6, Fernandez-Bussy S3,7. Ann Am Thorac Soc. 2018 Oct;15(10):1205-1216. doi: 10.1513/AnnalsATS.201801-045OC.

Accuracy of a novel histoplasmosis enzyme immunoassay to evaluate suspicious lung nodules. Deppen SA1, Massion PP2, Blume J3, Walker RC4, Antic S2, Chen H5, Durkin MM6, Wheat LJ6, Grogan EL7. Cancer Epidemiol Biomarkers Prev. 2018 Oct 19. pii: cebp.0169.2018. doi: 10.1158/1055-9965.EPI-18-0169. [Epub ahead of print]

Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. Slavin TP1, Banks KC1, Chudova D1, et al. J Clin Oncol. 2018 Oct 19:JCO1800328. doi: 10.1200/JCO.18.00328. [Epub ahead of print]

NSCLC SURGERY

Factors Associated with New Persistent Opioid Usage After Lung Resection. Brescia AA1, Harrington CA2, Mazurek A1, et al. Ann Thorac Surg. 2018 Oct 11. pii: S0003-4975(18)31466-8. doi: 10.1016/j.athoracsur.2018.08.057. [Epub ahead of print]

Preoperative albumin-to-globulin ratio predicts survival in patients with non-small-cell lung cancer after surgery. Zhang H1,2,3,4, Zhang B1,2,3,4, Zhu K5, et al. J Cell Physiol. 2018 Oct 14. doi: 10.1002/jcp.26766. [Epub ahead of print]

Preoperative thoracic muscle area on computed tomography predicts long-term survival following pneumonectomy for lung cancer. Troschel FM1, Kuklinski MW1, Knoll SJ2, et al. Interact Cardiovasc Thorac Surg. 2018 Oct 10. doi: 10.1093/icvts/ivy280. [Epub ahead of print]

Outcomes following resection of non-small cell lung cancer in octogenarians. Vazirani J1, Moraes J1, Barnett S2,3,4,5, et al. ANZ J Surg. 2018 Oct 2. doi: 10.1111/ans.14861. [Epub ahead of print]

Long-term results of robotic anatomical segmentectomy for early-stage non-small-cell lung cancer. Nguyen D1, Gharagozloo F2, Tempesta B2, Meyer M1, Gruessner A3. Eur J Cardiothorac Surg. 2018 Oct 15. doi: 10.1093/ejcts/ezy332. [Epub ahead of print]

Minimally invasive approaches do not compromise outcomes for pneumonectomy, a comparison utilizing the National Cancer Database. Hennon MW1, Kumar A2, Devisetty H2, D’Amico T3, Demmy TL1, Groman A4, Yendamuri S5. J Thorac Oncol. 2018 Oct 4. pii: S1556-0864(18)33176-9. doi: 10.1016/j.jtho.2018.09.024. [Epub ahead of print]

NSCLC – SYSTEMIC THERAPIES (CHEMOTHERAPY, TARGETED THERAPY, AND IMMUNOTHERAPY)

Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens. Goffin JR1, Nicholas G2, Mates M3, et al. Invest New Drugs. 2018 Oct 13. doi: 10.1007/s10637-018-0680-z. [Epub ahead of print]

Comparative efficacy of brigatinib versus ceritinib and alectinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small cell lung cancer. Reckamp K1, Lin HM2, Huang J2, Proskorovsky I3, Reichmann W2, Krotneva S3, Kerstein D2, Huang H2, Lee J4. Curr Med Res Opin. 2018 Oct 5:1-8. doi: 10.1080/03007995.2018.1520696. [Epub ahead of print]

Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non-small cell lung cancer after second-line chemotherapy treatment: A retrospective study. Zhang D1,2, Zhang C2, Huang J1,2, Guan Y2, Guo Q2. Thorac Cancer. 2018 Oct 19. doi: 10.1111/1759-7714.12898. [Epub ahead of print]

The Superior Antitumor Effect of Self-Assembled Paclitaxel Nano-filaments for Lung Cancer Cells. He M1, Zhu J1, Yu N2, Kong H1, Zeng X1, Xie W1, Xu H1. Curr Drug Deliv. 2018 Oct 16. doi: 10.2174/1567201815666181017094003. [Epub ahead of print]

Treatment Patterns by EGFR Mutation Status in Non-Small Cell Lung Cancer Patients in the USA: A Retrospective Database Analysis. Aguilar KM1, Winfree KB2, Muehlenbein CE3, Zhu YE2, Wilson T1, Wetmore S2, Nadler ES4. Adv Ther. 2018 Oct 19. doi: 10.1007/s12325-018-0811-0. [Epub ahead of print]

Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. Fucà G1, Galli G2, Poggi M2, et al. Target Oncol. 2018 Oct 10. doi: 10.1007/s11523-018-0599-5. [Epub ahead of print]

Severe pneumonitis refractory to steroids following anti-PD-1 immunotherapy. Andruska N1, Mahapatra L1, Hebbard C1, Patel P2, Paul V3. BMJ Case Rep. 2018 Oct 8;2018. pii: bcr-2018-225937. doi: 10.1136/bcr-2018-225937.

Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non-small cell lung cancer after second-line chemotherapy treatment: A retrospective study. Zhang D1,2, Zhang C2, Huang J1,2, Guan Y2, Guo Q2. Thorac Cancer. 2018 Oct 19. doi: 10.1111/1759-7714.12898. [Epub ahead of print]

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study. Hochmair MJ1, Morabito A2, Hao D3, et al. Future Oncol. 2018 Oct 19. doi: 10.2217/fon-2018-0711. [Epub ahead of print]

PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer. Takamori S1, Takada K2, Toyokawa G1, et al. Anticancer Res. 2018 Oct;38(10):5897-5901. doi: 10.21873/anticanres.12933.

A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies. Batenchuk C1, Albitar M2, Zerba K1, Sudarsanam S2, Chizhevsky V2, Jin C1, Burns V3. J Clin Pathol. 2018 Oct 1. pii: jclinpath-2018-205362. doi: 10.1136/jclinpath-2018-205362. [Epub ahead of print]

The Fast Real-time Assessment of Combination Therapies in Immuno-ONcology (FRACTION) program: innovative, high-throughput clinical screening of immunotherapies. Simonsen KL1, Fracasso PM2, Bernstein SH3, Wind-Rotolo M4, Gupta M5, Comprelli A6, Reilly TP7, Cassidy J8. Eur J Cancer. 2018 Nov;103:259-266. doi: 10.1016/j.ejca.2018.07.127. Epub 2018 Oct 3.

PD-L1 Expression in Non-Small-Cell Lung Cancer Including Various Adenocarcinoma Subtypes. Miyazawa T1, Marushima H1, Saji H1, Kojima K2, Hoshikawa M3, Takagi M3, Nakamura H1. Ann Thorac Cardiovasc Surg. 2018 Oct 3. doi: 10.5761/atcs.oa.18-00163. [Epub ahead of print]

NSCLC - RADIOTHERAPY

A Contemporary Update on the Role of Stereotactic Body Radiation Therapy (SBRT) for Liver Metastases in the Evolving Landscape of Oligometastatic Disease Management. Robin TP1, Raben D1, Schefter TE2. Semin Radiat Oncol. 2018 Oct;28(4):288-294. doi: 10.1016/j.semradonc.2018.06.009.

Identifying patterns of care for elderly patients with non-surgically treated stage III non-small cell lung cancer: an analysis of the national cancer database. Miller ED1, Fisher JL2, Haglund KE1, et al. Radiat Oncol. 2018 Oct 5;13(1):196. doi: 10.1186/s13014-018-1142-7.

Assessment of tumour response after stereotactic ablative radiation therapy for lung cancer: A prospective quantitative hybrid 18 F-fluorodeoxyglucose-positron emission tomography and CT perfusion study. Yang DM1,2,3, Palma D4,5, Louie A4,5, et al. J Med Imaging Radiat Oncol. 2018 Oct 3. doi: 10.1111/1754-9485.12807. [Epub ahead of print]

Radiation Dose Escalation in Accelerated Hyperfractionated Radiotherapy for Stage III Non-small-cell Lung Cancer. Wada K1, Kishi N2, Kanayama N2, Hirata T2, Morimoto M2, Konishi K2, Imamura F3, Teshima T2, Ogawa K4. Anticancer Res. 2018 Oct;38(10):5951-5958. doi: 10.21873/ anticanres.12941.

A matched-pair analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer versus early stage non-small cell lung cancer. Wang X1,2, Zamdborg L3, Ye H3, Grills IS3,4, Yan D3,4. BMC Cancer. 2018 Oct 10;18(1):962. doi: 10.1186/s12885-018-4865-9.

A method for optimizing planning target volume margins for patients receiving lung stereotactic body radiotherapy. Wierzbicki M1, Mathew L, Swaminath A. Phys Med Biol. 2018 Oct 2;63(19):195015. doi: 10.1088/1361-6560/aadf26.

Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer. Schild SE1, Fan W2, Stinchcombe TE3, et al. J Thorac Oncol. 2018 Oct 4. pii: S1556-0864(18)33173-3. doi: 10.1016/j.jtho.2018.09.021. [Epub ahead of print]

SMALL CELL LUNG CANCER - SCLC

Third-Line Nivolumab Monotherapy in Recurrent Small Cell Lung Cancer: CheckMate 032. Ready N1, Farago AF2, de Braud F3, et al. J Thorac Oncol. 2018 Oct 10. pii: S1556-0864(18)33181-2. doi: 10.1016/j.jtho.2018.10.003. [Epub ahead of print]

Topotecan monotherapy for the treatment of relapsed small cell lung cancer in elderly patients: A retrospective analysis. Imai H1, Yamada Y2, Minemura H3, et al. Thorac Cancer. 2018 Oct 3. doi: 10.1111/1759-7714.12884. [Epub ahead of print]

Final report of survival and late toxicities in the Phase I study of stereotactic body radiation therapy for peripheral T2N0M0 non-small cell lung cancer (JCOG0702). Onimaru R1, Onishi H2, Ogawa G3, et al. Jpn J Clin Oncol. 2018 Oct 1. doi: 10.1093/jjco/hyy141. [Epub ahead of print]

Prophylactic cranial irradiation for limited-stage small-cell lung cancer patients: secondary findings from the prospective randomized phase 3 CONVERT trial. Levy A1, Le Péchoux C2, Mistry H3, Martel-Lafay I4, Bezjak A5, Lerouge D6, Padovani L7, Taylor P8, Faivre-Finn C9. J Thorac Oncol. 2018 Oct 4. pii: S1556-0864(18)33171-X. doi: 10.1016/j.jtho.2018.09.019. [Epub ahead of print]

Is prophylactic cranial irradiation necessary in individuals suffering from surgically resected pT1-2N0M0 small cell lung cancer? Lu H1, Jiang Z2, Li C2. Ir J Med Sci. 2018 Oct 17. doi: 10.1007/s11845-018-1912-0. [Epub ahead of print]

A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients. Stinchcombe TE1, Fan W2, Schild SE3, Cancer. 2018 Oct 21. doi: 10.1002/cncr.31813. [Epub ahead of print]

Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study. Yan X1, Wang Q1, Wang H1, Li P1, Zhang G1, Zhang M1, Zheng X1, Yang J1, Zhang X1, Ma Z2. J Cancer Res Clin Oncol. 2018 Oct 6. doi: 10.1007/s00432-018-2764-8. [Epub ahead of print]

PALLIATIVE AND SUPPORTIVE CARE

Factors Affecting Racial Disparities in End-of-Life Care Costs Among Lung Cancer Patients: A SEER-Medicare-based Study. Karanth S1, Rajan SS1, Revere FL1, Sharma G2. Am J Clin Oncol. 2018 Oct 8. doi: 10.1097/COC.0000000000000485. [Epub ahead of print]

Postoperative Pneumonia Prevention in Pulmonary Resections: A Feasibility Pilot Study. Semenkovich TR1, Frederiksen C2, Hudson JL2, Subramanian M2, Kollef MH3, Patterson GA2, Kreisel D2, Meyers BF2, Kozower BD2, Puri V2. Ann Thorac Surg. 2018 Oct 3. pii: S0003-4975(18)31350-X. doi: 10.1016/j.athoracsur.2018.08.008. [Epub ahead of print]

Improving the delivery of physical activity services in lung cancer: A qualitative representation of the patient’s perspective. Granger CL1,2, Parry SM1, Edbrooke L1,3, Abo S2, Leggett N1,2, Dwyer M1, Denehy L3,4. Eur J Cancer Care (Engl). 2018 Oct 4:e12946. doi: 10.1111/ecc.12946. [Epub ahead of print]

Promotion of Behavioral Change and the Impact on Quality of Life in Elderly Patients with Advanced Cancer: A Physical Activity Intervention of the Multimodal Nutrition and Exercise Treatment for Advanced Cancer Program. Mouri T1, Naito T2, Morikawa A3, Tatematsu N4, Miura S5, Okayama T6, Omae K7, Takayama K1. Asia Pac J Oncol Nurs. 2018 Oct-Dec;5(4):383-390. doi: 10.4103/apjon.apjon_21_18.

Trajectory of insomnia symptoms in older adults with lung cancer: using mixed methods. Dean GE1, Ziegler P2, Chen H3, Steinbrenner LM2,4, Dickerson SS5. Support Care Cancer. 2018 Oct 15. doi: 10.1007/s00520-018-4488-3. [Epub ahead of print]

Impact of Cancer Cachexia on Hospitalization-associated Physical Inactivity in Elderly Patients with Advanced Non-small-cell Lung Cancer. Morikawa A1, Naito T2, Sugiyama M1, Okayama T3, Aoyama T4, Tanuma A3, Omae K5, Takahashi T2. Asia Pac J Oncol Nurs. 2018 Oct-Dec;5(4):377-382. doi: 10.4103/apjon.apjon_20_18.

Psychosocial Support in Cancer Cachexia Syndrome: The Evidence for Supported Self-Management of Eating Problems during Radiotherapy or Chemotherapy Treatment. Hopkinson J1. Asia Pac J Oncol Nurs. 2018 Oct-Dec;5(4):358-368. doi: 10.4103/apjon.apjon_12_18.

COMPLEMENTARY & ALTERNATIVE THERAPY

Chemical composition and biological activity of extracts from fruiting bodies and mycelial cultures of Fomitopsis betulina. Sułkowska-Ziaja K1, Szewczyk A2, Galanty A3, Gdula-Argasińska J4, Muszyńska B2. Mol Biol Rep. 2018 Oct 13. doi: 10.1007/s11033-018-4420-4. [Epub ahead of print]

Complementary Medicine, Refusal of Conventional Cancer Therapy, and Survival Among Patients With Curable Cancers. Johnson SB1, Park HS1, Gross CP2, Yu JB1,2. AMA Oncol. 2018 Oct 1;4(10):1375-1381. doi: 10.1001/jamaoncol.2018.2487.

Bioactivity-guided isolation of ginsenosides from Korean Red Ginseng with cytotoxic activity against human lung adenocarcinoma cells. Yu JS1, Roh HS2, Baek KH2, et al. J Ginseng Res. 2018 Oct;42(4):562-570. doi: 10.1016/j.jgr.2018.02.004. Epub 2018 Feb 16.

MISCELLANEOUS WORKS

Smoking and Lung Cancer Mortality in the United States From 2015 to 2065: A Comparative Modeling Approach. Jeon J1, Holford TR2, Levy DT3, Feuer EJ4, Cao P1, Tam J1, Clarke L5, Clarke J5, Kong CY6, Meza R1. Ann Intern Med. 2018 Oct 9. doi: 10.7326/M18-1250. [Epub ahead of print]

Pilot Randomized Trial of a Pharmacy Intervention for Older Adults with Cancer. Nipp RD1, Ruddy M2, Fuh CX2, et al. Oncologist. 2018 Oct 19. pii: theoncologist.2018-0408. doi: 10.1634/theoncologist.2018-0408. [Epub ahead of print]

 

The unintended impact of smoking-risk information on concerns about radon: A randomized controlled trial. Gold JM1, Stuart JO1, Thiem KC1, Field RW2, Fernandez-Baca J3, Windschitl PD1. Health Psychol. 2018 Oct 18. doi: 10.1037/hea0000681. [Epub ahead of print]

Impact Of The Affordable Care Act (Aca) Medicaid Expansion On Cancer Admissions and Surgeries. Eguia E1,2, Cobb AN1,2, Kothari AN2, Molefe A3, Afshar M4, Aranha GV5, Kuo PC6. Ann Surg. 2018 Oct;268(4):584-590. doi: 10.1097/SLA.0000000000002952.

Reductions in Cigarettes per Day and Mortality Among Older Adults in The United States. Inoue-Choi M1, Hartge P1, Park Y2, Abnet CC1, Freedman ND1. Am J Epidemiol. 2018 Oct 9. doi: 10.1093/aje/kwy227. [Epub ahead of print]

 

A qualitative study of Realtor knowledge, attitudes, and practices related to radon health effects: implications for comprehensive cancer control. Momin B1, McNaughton C2, Galanek JD3, Neri A4, Gallaway MS5, Puckett M5. Cancer Causes Control. 2018 Oct 3. doi: 10.1007/s10552-018-1086-0. [Epub ahead of print]

 

Archives